Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.

MLA

Butt, Jawad H., et al. “Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.” Circulation, vol. 146, no. 16, Oct. 2022, pp. 1210–24. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.122.061754.

APA

Butt, J. H., Jhund, P. S., Belohlávek, J., de Boer, R. A., Chiang, C.-E., Desai, A. S., Drożdż, J., Hernandez, A. F., Inzucchi, S. E., Katova, T., Kitakaze, M., Kosiborod, M. N., Lam, C. S. P., Maria Langkilde, A., Lindholm, D., Bachus, E., Martinez, F., Merkely, B., Petersson, M., & Saraiva, J. F. K. (2022). Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 146(16), 1210–1224. https://doi.org/10.1161/CIRCULATIONAHA.122.061754

Chicago

Butt, Jawad H., Pardeep S. Jhund, Jan Belohlávek, Rudolf A. de Boer, Chern-En Chiang, Akshai S. Desai, Jarosław Drożdż, et al. 2022. “Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.” Circulation 146 (16): 1210–24. doi:10.1161/CIRCULATIONAHA.122.061754.